september 9, 2020
EO2401 is an innovative, off-the-shelf microbiome-antigen (‘OncoMimic’) based immunotherapy candidate EO2401 combines three ‘OncoMimics’ designed to trigger the immune system into recognizing tumor cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response Clinical trial with EO2401 now underway in two cancer indications: brain cancer (glioblastoma) and adrenal tumors Paris, France and Cambridge, MA,...


Fedme sidder i hjernen
24. september 2020
442 vikingeskeletter fik en tur i DNA-maskinen – nu revideres historien om vikingekulturen
16. september 2020
Håb om at kunne kurere type 2 diabetes med indsprøjtning i hjernen
7. september 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge